Eosinophilic colitis is a heterogeneous disorder presenting in childhood or adulthood and a feature that is pronounced eosinophilic infiltration in the colon, which may be segmental or diffuse. As a research service provider, Protheragen provides extensive multidisciplinary services to assist in the development of therapies for eosinophilic colitis. We aid customers at various stages of the development of drugs from drug discovery to preclinical research.

Overview of Eosinophilic Colitis

Eosinophilic colitis is the least frequent type of eosinophilic gastrointestinal disorder, with an estimated prevalence of 2.1-3.3 cases per 100,000 people. The condition possesses a broad array of features like abdominal pain, diarrhea with or without blood, and weight loss. Eosinophilic colitis has three forms determined by identification of the infiltrated eosinophils in the ulcerative colon's wall of different layers. These are mucosal eosinophilic colitis, muscular or transmural, and serosal eosinophilic colitis.

Fig.1 Antibody targeting in eosinophil-associated diseases. (Pitlick, M. M., et al., 2022)

Pathogenesis of Eosinophilic Colitis

The cause and development of eosinophilic colitis is still fuzzy and multi-factor involving a Th2 CD4⁺ mechanism. In children, eosinophilic colitis is more likely to be food allergy associated, mostly IgE driven, like cow's milk allergy. In adults, on the other hand, the pathogenesis is thought to be primarily CD4⁺ mediated.

Therapeutics Development for Eosinophilic Colitis

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Leverage the latest technologies and methodologies in drug development to ensure that our clients have access to the most advanced tools and techniques available. Our services in this area are specifically tailored to support the development of potential therapeutics for this challenging condition, including diagnostic, therapeutic, and disease model development services.

Therapeutic Development Services

• Small Molecule Drug
• Cell Therapy Development
• Gene Therapy Development
• Therapeutic Antibody

• Therapeutic Peptide
• Therapeutic Protein
• Microbiome Therapeutic
• More

Animal Model Development Services

Animal models aid researchers in understanding the disease process of eosinophilic colitis, developing possible drugs, and exploring therapeutic measures. Our company focuses on animal model development for eosinophilic colitis to enable preclinical research and therapy development for this disease.

Induced Models

Developed chronic eosinophilic colitis animal model by either providing dextran sodium sulfate (DSS) in drinking water or delivering tri-nitrobenzene sulfonate (TNBS) intra-rectally.

Genetically Engineering Models

Genetically engineered animal models involve modifying the animal's genome to replicate specific genetic mutations or alterations associated with eosinophilic colitis, such as the IL-5 transgenic model.

Protheragen's team carries out numerous services to assist and support the important processes for drug creation that involve the therapeutic of eosinophilic colitis, such as pharmacokinetics and drug safety testing. We understand that drug development projects differ from one another; hence, we strive to develop unique solutions for each of our clients and their goals. If you would like to read more about what services we offer and our prices, do not hesitate to get in touch.

Reference

• Pitlick, Mitchell M et al. "Current and emerging biologic therapies targeting eosinophilic disorders." The World Allergy Organization journal 15.8 (2022): 100676.
• Páramo-Zunzunegui, Javier et al. "Eosinophilic colitis: an infrequent disease with difficult diagnose." BMJ case reports 13.9 (2020): e235804.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.